FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarNovartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its Share XFDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarhttps://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/
Bridging the gap between pharma and the NHS in MSJanette Curlis is a Multiple Sclerosis Nurse Advisor (MSNA) at Biogen, helping to support the company’s Multiple Sclerosis Share XBridging the gap between pharma and the NHS in MShttps://pharmaphorum.com/views-analysis-patients/bridging-gap-between-pharma-nhs-in-ms/
FDA panel unimpressed with data for Alzheimer’s drug aducanumabThe FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors Share XFDA panel unimpressed with data for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/fda-sceptical-on-biogen-eisai-data-for-alzheimers-drug-aducanumab/
China’s Green Valley prepares US trial of Alzheimer’s drug inspired by algaeAs an influential panel of FDA-appointed experts prepares its verdict on Biogen’s Alzheimer’s drug, a little known China-based Share XChina’s Green Valley prepares US trial of Alzheimer’s drug inspired by algaehttps://pharmaphorum.com/news/chinas-green-valley-prepares-us-trial-of-alzheimers-drug-inspired-by-algae/
Trials and tribulations in Biogen’s Alzheimer’s drug reviewsRegulatory reviews of Biogen’s Alzheimer’s drug aducanumab are now ongoing on both sides of the Atlantic, but debate Share XTrials and tribulations in Biogen’s Alzheimer’s drug reviewshttps://pharmaphorum.com/news/trials-and-tribulations-in-biogens-alzheimers-drug-reviews/
Biogen teams up with gene-editing startup Scribe on ALS programmeScribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 Share XBiogen teams up with gene-editing startup Scribe on ALS programmehttps://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/
Roche takes on pricey rivals as FDA approves SMA drugRoche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) Share XRoche takes on pricey rivals as FDA approves SMA drughttps://pharmaphorum.com/news/roche-takes-on-pricey-rivals-as-fda-approves-sma-drug/
Biogen’s shares surge again as FDA hurries Alzheimer’s drug reviewBiogen’s Alzheimer’s drug aducanumab could be on the market in the next few months after the FDA accepted Share XBiogen’s shares surge again as FDA hurries Alzheimer’s drug reviewhttps://pharmaphorum.com/news/biogens-shares-surge-again-as-fda-hurries-alzheimers-drug-review/
Biogen signs $2.1 billion Parkinson’s disease deal with DenaliBiogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in Share XBiogen signs $2.1 billion Parkinson’s disease deal with Denalihttps://pharmaphorum.com/news/biogen-signs-2-1-billion-parkinsons-disease-deal-with-denali/
